Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Multi-Species Imaging Module

By Drug Discovery Trends Editor | April 16, 2010

VisEn Medical Inc., a leader in fluorescence imaging solutions from research through medicine, has expanded its leading fluorescence molecular tomography (FMT) imaging platform with an FMT Multi-Species Imaging Module, to extend FMT imaging and related applications into larger preclinical animal models.  VisEn also announced that it will be presenting new study results from its recently-launched Cat B 750 FAST and Annexin-Vivo fluorescence imaging agents at the AACR (American Association of Cancer Research) 101st Annual Meeting, highlighting translational imaging advances in leading oncology research.  The AACR Annual Meeting is being held in Washington, DC from April 17 – 21, 2010.

FMT Multi-Species Imaging Module
VisEn’s new FMT Multi-Species Imaging Module enables FMT quantitative imaging in an expanded range of larger preclinical animal models, including rats, hamsters and guinea pigs, thereby further extending FMT imaging research into areas typically studied in larger animals. These areas include metabolic, toxicology and biodistribution studies, as well as certain vaccines, and obesity, bone and hypertension studies.  The Multi-Species Imaging Module is designed to be compatible with all of VisEn’s fluorescence imaging agents, and will be available later in 2010. 

Advanced Application Data Presented on VisEn’s Cat B 750 FAST and Annexin-Vivo Imaging Agents for Oncology Research
VisEn will present advanced data at the AACR Annual Meeting on its recently-launched Cat B 750 FAST and Annexin-Vivo fluorescence imaging agents, including studies titled “In vivo near-infrared fluorescent quantification of therapy-induced apoptosis using Annexin-Vivo 750,” and “Fast-activating Cathepsin B optical agent for quantitative in vivo imaging of tumor and therapeutic response.”

Jeffrey Peterson, Ph.D., VisEn’s Vice President of Applied Biology, said “We developed an Annexin red imaging agent, Annexin-Vivo 750, which targets Annexin V, a well-characterized biomarker for apoptosis. The results presented at the AACR Annual Meeting highlight how Annexin-Vivo 750 enables the rapid in vivo assessment of therapeutic efficacy in key cancer models. In addition, the agent is increasingly being used in researching a variety of other pathological conditions involving apoptosis including stroke, atherosclerosis, myocardial ischemia, and liver toxicity.”

The second imaging agent to be profiled at the AACR Annual Meeting, Cat B 750 FAST, utilizes VisEn’s FAST activatable agent platform to target Cathepsin (Cat) B, a lysosomal cysteine protease highly over-expressed in cancers and premalignant lesions and associated with cancer growth, neo-vascularization and metastasis. “This recent study illustrates the potential of VisEn’s Cat B 750 FAST agent and of the FMT quantitative tomography platform to non-invasively quantify the underlying biology of tumorigenic processes in real time, and distinguishes an increase in Cat B and tumor-associated macrophage activity following cytotoxic therapy treatment,” said Peterson. “Quantification of Cat B activity in the tumor environment is a valuable biomarker for the detection of cancer and metastases, as well as the development and monitoring of anti-cancer therapies”.

VisEn Medical Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE